Kessler Topaz Meltzer & Check, LLP: Investigation on Behalf of ChemoCentryx, Inc. Shareholders
Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of purchasers of ChemoCentryx, Inc. (“ChemoCentryx”) (NASDAQ: CCXI) securities between November 25, 2019 and May 3, 2021.
ChemoCentryx investors may receive additional information about this investigation by clicking the link "Submit Your Information" above.
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer.
On May 4, 2021, the U.S. Food and Drug Administration (“FDA”) released a “Briefing Document” concerning ChemoCentryx’s drug candidate avacopan, which is in development for the treatment of adult patients with anti-neutrophil cytoplasmic autoantibody vasculitis. In the Briefing Document, the FDA stated, “[a]lthough primary efficacy comparisons were statistically significant, the review team has identified several areas of concern, raising uncertainties about the interpretability of the[] data and the clinical meaningfulness of the[] results.”
Following this news, ChemoCentryx’s stock price is down approximately 45% during intraday trading on May 4, 2021.
If you wish to discuss this investigation, please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453 or Adrienne Bell, Esq. (484) 270-1435; toll-free at (844) 887-9500; or via e-mail at [email protected].
Please complete this form relating to your transactions for ChemoCentryx, Inc. (NASDAQ: CCXI) securities between November 25, 2019 and May 3, 2021, inclusive.
You may also contact James Maro, Jr., Esq. or Adrienne Bell, Esq. at 610.667.7706 or toll free at 844.887.9500, or you may submit your information via email at [email protected], or you may click here to print a PDF of this form.